Search results

1

Vascular complications in patients with Autosomal Dominant Polycystic Kidney Disease. A review of the literature and current clinical recommendations

100%

Koska-Ścigała A., Zdrojewski Ł., Jankowska M., Dębska-Ślizień A.

European Journal of Translational and Clinical Medicine

|

2020

|

vol. 3

|

issue 2

64-71

EN

Autosomal dominant polycystic kidney disease is the most common genetic cause of renal failure. Apart from kidney involvement, patients are at risk of extra-renal manifestations, including vascular lesions. The etiology of vascular changes is diverse and depends, among other factors, on polycystin gene mutation, increased activity of the renin-angiotensin-aldosterone system and the occurrence of hypertension. The observed vascular system complications include cerebral artery aneurysms, cervico-encephalic arteries' dissection, aortic aneurysm and dissection and intracranial arterial dolichoectasia. This article discusses the etiopathogenesis, symptomatology, principles of prevention and treatment of the aforementioned diseases of the vascular system accompanying polycystic kidney disease.

2

Protocol for a scoping review of fecal microbiota transplantation from patients into animals

88%

Ruszkowski J., Kachlik Z., Walaszek M., Storman D., Dębska-Ślizień A.

European Journal of Translational and Clinical Medicine

|

2023

|

vol. 6

|

issue 1

87-91

EN

Microbiota studies have uncovered numerous associations between human gut microbes and health-related outcomes. However, since most of these correlations were observed in cross-sectional studies, the causal infe rence is limited. The causal contribution of microbiota can be evidenced through disease induction or exacerbaiton in animal models aeftr fecal microbiota transplantation (FMT) from patients. In this article we present a protocol for a scoping review on the subject of FMT from humans to animals. Besides assessing how the published studies were conducted, in that scoping review we aim to find out whether enough literature exists to conduct a systematic review of the evidence for microbiota participation in the pathophysiology of any human non-infectious disease or phenotypic trait. We will conduct searches on the Web of Science plaotfrm and databases: MEDLINE, Scopus, EMBASE. Citation chasing of included studies will be done. We will include studies assessing the eefcts of FMT collected from people with certain medical conditions on animals. Studies that recruited only healthy humans or used other animals as donors will be excluded. The results of this literature search will be tabulated and discussed. Moreover, we will provide a short list of human non-infectious diseases or traits with the highest number of FMT patient-to-animal studies. Ruszkowski J, Kachlik Z, Walaszek M, Storman D, Dębska-Ślizień A. Protocol for a scoping review of fecal microbiota transplantation from patients into animals. Eur J Transl Clin Med. 2023;6(1):87-91.

3

Obesity in work-up of kidney transplant candidates – review of clinical practice guidelines

76%

Dobrzycka M., Spychalski P., Łącka M., Proczko-Stepaniak M., Dębska-Ślizień A., Kaska Ł., Kobiela J.

European Journal of Translational and Clinical Medicine

|

2020

|

vol. 3

|

issue 2

72-79

EN

Background: Incidence of morbid obesity is rising worldwide. Current clinical practice guidelines for the pre-transplant evaluation of end-stage kidney disease (ESKD) patients lack clear recommendations on morbid obesity. Material and methods: The aim of this review was to summarize the current guidelines on the role and treatment of obesity in kidney transplant recipients. Eight current national and international clinical practice guidelines were identified in a comprehensive literature search. Results: All guidelines underline early detection of obesity and obesity-related comorbidities in ESKD patients. Only two guidelines explored the role of weight-loss surgery, however due to the lack of sufficient evidence no formal recommendation of surgical procedure was given. Conclusions: Diagnosis and treatment of obesity remains underappreciated in the current guidelines, most of which do not include pharmacological and surgical interventions. High-quality evidence is warranted to assess the role of weight-loss including surgery in ESKD patients and to update the recommendations in future guidelines.

4

The use of over-the-counter analgesics in patients with chronic kidney disease

64%

Jakimowicz-Tylicka M., Chmielewski M., Kuźmiuk-Glembin I., Skonieczny P., Dijakiewicz G., Zdrojewska G., Rutkowski B., Tylicki L., Dębska-Ślizień A.

|

2019

|

vol. 1

|

issue 2

11-16

EN

Background Analgesics can be sold following medical prescription, but also as over-the-counter (OTC) medications. In patients with chronic kidney disease (CKD), their use could potentially be associated with increased risk of side-effects, due to impaired renal elimination. The aim was to evaluate the epidemiology and indications for the use of OTC analgesics, and the knowledge of their side-effects in patients with CKD. Material and methods A cross-sectional, controlled survey on the use of OTC analgesic drugs was conducted among 180 CKD patients (stage 1-5, dialysis, kidney transplant), compared to 60 controls. Results The proportion of patients using OTC analgesics on a regular basis was higher in the CKD group, compared to controls (18.9% vs. 10.0%, p<0.02). The major indications included musculoskeletal issues, followed by headaches and other. Subgroup analysis revealed that analgesic use was lowest among transplanted patients, in comparison to CKD stage 1-5, and dialysis subjects (10%, 20%, 26%, respectively, p=0.06). Less than half of CKD patients and controls declared any knowledge on potential side-effects of analgesic drugs (45.6% vs. 40.0%, NS). Conclusions The use of OTC analgesics among patients with CKD is higher than in subjects without CKD, with the exception of transplanted patients. The knowledge on the potential side-effect of analgesics is limited.

5

The use of over-the-counter analgesics in patients with chronic kidney disease

64%

Jakimowicz-Tylicka M., Chmielewski M., Kuźmiuk-Glembin I., Skonieczny P., Dijakiewicz G., Zdrojewska G., Rutkowski B., Tylicki L., Dębska-Ślizień A.

|

EN

Background: Analgesics can be sold following medical prescription, but also as over-the-counter (OTC) medications. In patients with chronic kidney disease (CKD), their use could potentially be associated with increased risk of side-effects, due to impaired renal elimination. The aim was to evaluate the epidemiology and indications for the use of OTC analgesics, and the knowledge of their side-effects in patients with CKD. Material and methods: A cross-sectional, controlled survey on the use of OTC analgesic drugs was conducted among 180 CKD patients (stage 1-5, dialysis, kidney transplant), compared to 60 controls. Results: The proportion of patients using OTC analgesics on a regular basis was higher in the CKD group, compared to controls (18.9% vs. 10.0%, p<0.02). The major indications included musculoskeletal issues, followed by headaches and other. Subgroup analysis revealed that analgesic use was lowest among transplanted patients, in comparison to CKD stage 1-5, and dialysis subjects (10%, 20%, 26%, respectively, p=0.06). Less than half of CKD patients and controls declared any knowledge on potential side-effects of analgesic drugs (45.6% vs. 40.0%, NS). Conclusions: The use of OTC analgesics among patients with CKD is higher than in subjects without CKD, with the exception of transplanted patients. The knowledge on the potential side-effect of analgesics is limited.

6

SARS-CoV-2 infection in vaccinated maintenance hemodialysis patients despite anti-spike seroconversion: a report of 3 breakthrough cases

52%

Biedunkiewicz B., Tylicki L., Puchalska-Reglińska E., Dąbrowska M., Ślizień W., Kubanek A., Rąbalski Ł., Kosiński M., Grzybek M., Renke M., Dębska-Ślizień A.

European Journal of Translational and Clinical Medicine

|

2022

|

vol. 5

|

issue 1

12-16

EN

Chronically hemodialyzed (HD) patients are at a high risk of developing very severe forms of COVID-19 disease. In this article we describe three HD patients (all males, aged 70, 70 and 74 years) vaccinated intramuscularly with a two-dose mRNA BNT162b2 vaccine; BionTech/Pfizer Comirnaty, in whom subsequent breakthrough SARS-CoV-2 infections developed. All patients achieved post-vaccine seroconversion for anti-spike antibodies with IgG titers of 445, 227 and 92.5 AU/mL (cut-off, 13 AU/mL) case 1, 2 and 3 respectively. SARS-CoV-2 infection was diagnosed 44, 28 and 48 days after the second dose of BNT162b2 and confirmed with the polymerase-chain-reaction (PCR) test. Two asymptomatic patients underwent this test because of their direct contact with a person with confirmed COVID-19. The third patient reported only a non-significant drop in oxygen saturation, and was hospitalized (case 3). All these patients were characterized by a low post-vaccination neutralizing antibody titer and a high production of these antibodies after falling ill (795, 845 and 5770). Perhaps this production of antibodies is responsible for the mild course of the disease, and the likely reduction of mortality. These breakthrough cases in no way undermine the importance of the vaccinations, and on the contrary argue for their urgency.

Refine search results

Vascular complications in patients with Autosomal Dominant Polycystic Kidney Disease. A review of the literature and current clinical recommendations

Protocol for a scoping review of fecal microbiota transplantation from patients into animals

Obesity in work-up of kidney transplant candidates – review of clinical practice guidelines

The use of over-the-counter analgesics in patients with chronic kidney disease

The use of over-the-counter analgesics in patients with chronic kidney disease

SARS-CoV-2 infection in vaccinated maintenance hemodialysis patients despite anti-spike seroconversion: a report of 3 breakthrough cases